• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Vaginitis - Pipeline Review, H2 2012 Product Image

Vaginitis - Pipeline Review, H2 2012

  • ID: 2335198
  • November 2012
  • 33 pages
  • Global Markets Direct

Vaginitis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Vaginitis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Vaginitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vaginitis. Vaginitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Vaginitis.
- A review of the Vaginitis products under development by companies and universities/research institutes based on information derived from company and READ MORE >

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Vaginitis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Vaginitis 7
Vaginitis Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Pre-Clinical Stage Products 11
Comparative Analysis 11
Vaginitis Therapeutics – Products under Development by Companies 12
Companies Involved in Vaginitis Therapeutics Development 13
Centaur Pharmaceuticals Pvt. Ltd. 13
BioDiem Ltd 14
Lumavita AG 15
NanoBio Corporation 16
Lee's Pharmaceutical Holdings Limited 17
FunZyme BioTechnologies S.A. 18
Vaginitis – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
Drug For Vaginitis - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Miconazole Nitrate + Neomycin Sulphate + Tinidazole - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
BDM-I - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ZK-004 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Vaginitis Therapeutics – Drug Profile Updates 29
Vaginitis Therapeutics - Dormant Products 30
Vaginitis – Product Development Milestones 31
Featured News & Press Releases 31
Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables
Number of Products Under Development for Vaginitis, H2 2012 7
Products under Development for Vaginitis – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
Centaur Pharmaceuticals Pvt. Ltd., H2 2012 13
BioDiem Ltd, H2 2012 14
Lumavita AG, H2 2012 15
NanoBio Corporation, H2 2012 16
Lee's Pharmaceutical Holdings Limited, H2 2012 17
FunZyme BioTechnologies S.A., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Vaginitis Therapeutics – Drug Profile Updates 29
Vaginitis Therapeutics – Dormant Products 30

List of Figures
Number of Products under Development for Vaginitis, H2 2012 7
Products under Development for Vaginitis – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Pre-Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos